Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    February 2019
  1. WANG J, Dong R, Li K
    Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 12:JCO1801385. doi: 10.1200/JCO.18.01385.
    PubMed     Text format    


  2. FLINN IW, Miller CB, Ardeshna KM, Tetreault S, et al
    DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1800915. doi: 10.1200/JCO.18.00915.
    PubMed     Text format     Abstract available


  3. ADAMS HJA, Kwee TC
    A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1801830. doi: 10.1200/JCO.18.01830.
    PubMed     Text format    


  4. SORIGUE M, Sancho JM
    Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?
    J Clin Oncol. 2019 Feb 8:JCO1801761. doi: 10.1200/JCO.18.01761.
    PubMed     Text format    


  5. BICCLER JL, Glimelius I, Eloranta S, Smeland KB, et al
    Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
    J Clin Oncol. 2019 Feb 6:JCO1801652. doi: 10.1200/JCO.18.01652.
    PubMed     Text format     Abstract available


  6. O'CONNOR OA, Ozcan M, Jacobsen ED, Roncero JM, et al
    Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899.
    PubMed     Text format     Abstract available


    January 2019
  7. COOK LB, Fuji S, Hermine O, Bazarbachi A, et al
    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
    J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501.
    PubMed     Text format     Abstract available


  8. ANSELL SM, Minnema MC, Johnson P, Timmerman JM, et al
    Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    J Clin Oncol. 2019 Jan 8:JCO1800766. doi: 10.1200/JCO.18.00766.
    PubMed     Text format     Abstract available


  9. GERSON JN, Handorf E, Villa D, Gerrie AS, et al
    Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    J Clin Oncol. 2019 Jan 7:JCO1800690. doi: 10.1200/JCO.18.00690.
    PubMed     Text format     Abstract available


    December 2018
  10. ADAMS HJA, Kwee TC
    Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed.
    J Clin Oncol. 2018 Dec 28:JCO1801134. doi: 10.1200/JCO.18.01134.
    PubMed     Text format    


  11. JACOBSON CA
    CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 13:JCO1801457. doi: 10.1200/JCO.18.01457.
    PubMed     Text format     Abstract available


  12. SHA C, Barrans S, Cucco F, Bentley MA, et al
    Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
    J Clin Oncol. 2018 Dec 3:JCO1801314. doi: 10.1200/JCO.18.01314.
    PubMed     Text format     Abstract available


  13. CHAN WC
    Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801910. doi: 10.1200/JCO.18.01910.
    PubMed     Text format    


  14. ENNISHI D, Jiang A, Boyle M, Collinge B, et al
    Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801583. doi: 10.1200/JCO.18.01583.
    PubMed     Text format     Abstract available


    November 2018
  15. SARKOZY C, Maurer MJ, Link BK, Ghesquieres H, et al
    Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    J Clin Oncol. 2018 Nov 27:JCO1800400. doi: 10.1200/JCO.18.00400.
    PubMed     Text format     Abstract available


  16. SORIGUE M, Sancho JM
    Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography.
    J Clin Oncol. 2018 Nov 26:JCO1800854. doi: 10.1200/JCO.18.00854.
    PubMed     Text format    


    October 2018
  17. DAVIDS MS, von Keudell G, Portell CA, Cohen JB, et al
    Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359.
    PubMed     Text format    


  18. ALDERUCCIO JP, Zhao W, Desai A, Gallastegui N, et al
    Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.
    J Clin Oncol. 2018 Oct 12:JCO1800138. doi: 10.1200/JCO.18.00138.
    PubMed     Text format     Abstract available


  19. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
    J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
    PubMed     Text format     Abstract available


  20. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122.
    PubMed     Text format     Abstract available


    September 2018
  21. GISSELBRECHT C
    Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
    J Clin Oncol. 2018 Sep 17:JCO1800498. doi: 10.1200/JCO.18.00498.
    PubMed     Text format    


  22. ADAMS HJA, Kwee TC
    Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 17:JCO1800323. doi: 10.1200/JCO.18.00323.
    PubMed     Text format    


  23. EVENS AM, Advani RH, Helenowski IB, Fanale M, et al
    Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 4:JCO2018790139. doi: 10.1200/JCO.2018.79.0139.
    PubMed     Text format     Abstract available


    August 2018
  24. YANG JC, Yahalom J
    Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy?
    J Clin Oncol. 2018 Aug 28:JCO2018793075. doi: 10.1200/JCO.2018.79.3075.
    PubMed     Text format    


  25. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Aug 20:JCO2018785246. doi: 10.1200/JCO.2018.78.5246.
    PubMed     Text format     Abstract available


    July 2018
  26. WEIBULL CE, Johansson ALV, Eloranta S, Smedby KE, et al
    Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.
    J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514.
    PubMed     Text format     Abstract available


  27. SASSE S, Goergen H, Plutschow A, Boll B, et al
    Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
    J Clin Oncol. 2018 Jul 10:JCO2018787192. doi: 10.1200/JCO.2018.78.7192.
    PubMed     Text format     Abstract available


  28. SHI Q, Schmitz N, Ou FS, Dixon JG, et al
    Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    J Clin Oncol. 2018 Jul 5:JCO2018779124. doi: 10.1200/JCO.2018.77.9124.
    PubMed     Text format     Abstract available


  29. MACMANUS M, Fisher R, Roos D, O'Brien P, et al
    Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
    J Clin Oncol. 2018 Jul 5:JCO2018779892. doi: 10.1200/JCO.2018.77.9892.
    PubMed     Text format     Abstract available


    June 2018
  30. FRIEDBERG JW
    Progress in Advanced-Stage Follicular Lymphoma.
    J Clin Oncol. 2018 Jun 1:JCO2018793083. doi: 10.1200/JCO.2018.79.3083.
    PubMed     Text format    


  31. HIDDEMANN W, Barbui AM, Canales MA, Cannell PK, et al
    Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    J Clin Oncol. 2018 Jun 1:JCO2017768960. doi: 10.1200/JCO.2017.76.8960.
    PubMed     Text format     Abstract available


    May 2018
  32. GOPAL AK, Schuster SJ, Fowler NH, Trotman J, et al
    Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    J Clin Oncol. 2018 May 31:JCO2017768853. doi: 10.1200/JCO.2017.76.8853.
    PubMed     Text format     Abstract available


  33. MESGUICH C, Bouabdallah K, Milpied N, Hindie E, et al
    Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018786780. doi: 10.1200/JCO.2018.78.6780.
    PubMed     Text format    


  34. ADAMS HJA, Kwee TC
    Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018782524. doi: 10.1200/JCO.2018.78.2524.
    PubMed     Text format    


  35. MERRYMAN RW, LaCasce AS
    Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.
    J Clin Oncol. 2018 May 22:JCO2018789362. doi: 10.1200/JCO.2018.78.9362.
    PubMed     Text format    


  36. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed     Text format    


  37. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Text format     Abstract available


    April 2018
  38. MAURER MJ, Ghesquieres H, Link BK, Jais JP, et al
    Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
    J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198.
    PubMed     Text format     Abstract available


    March 2018
  39. CHESON BD, Chua N, Mayer J, Dueck G, et al
    Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656.
    PubMed     Text format     Abstract available


  40. ARMAND P, Engert A, Younes A, Fanale M, et al
    Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol. 2018 Mar 27:JCO2017760793. doi: 10.1200/JCO.2017.76.0793.
    PubMed     Text format     Abstract available


    February 2018
  41. ROEMER MGM, Redd RA, Cader FZ, Pak CJ, et al
    Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    J Clin Oncol. 2018 Feb 2:JCO2017773994. doi: 10.1200/JCO.2017.77.3994.
    PubMed     Text format     Abstract available


    January 2018
  42. GALLAMINI A, Tarella C, Viviani S, Rossi A, et al
    Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607
    J Clin Oncol. 2018 Jan 23:JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
    PubMed     Text format     Abstract available


  43. SHADMAN M, Li H, Rimsza L, Leonard JP, et al
    Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    J Clin Oncol. 2018 Jan 22:JCO2017745083. doi: 10.1200/JCO.2017.74.5083.
    PubMed     Text format     Abstract available


  44. BOLLARD CM, Tripic T, Cruz CR, Dotti G, et al
    Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
    J Clin Oncol. 2018 Jan 9:JCO2017743179. doi: 10.1200/JCO.2017.74.3179.
    PubMed     Text format     Abstract available


    November 2017
  45. LUMINARI S, Ferrari A, Manni M, Dondi A, et al
    Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
    PubMed     Text format     Abstract available


    October 2017
  46. MAURER MJ, Ellin F, Srour L, Jerkeman M, et al
    International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2017 Oct 26:JCO2017738195. doi: 10.1200/JCO.2017.73.8195.
    PubMed     Text format     Abstract available


  47. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2017 Oct 4:JCO2017754648. doi: 10.1200/JCO.2017.75.4648.
    PubMed     Text format     Abstract available


    September 2017
  48. HERRERA AF, Armand P
    Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
    J Clin Oncol. 2017 Sep 21:JCO2017745281. doi: 10.1200/JCO.2017.74.5281.
    PubMed     Text format     Abstract available


  49. SALZ T, Zabor EC, de Nully Brown P, Dalton SO, et al
    Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2017 Sep 18:JCO2017724211. doi: 10.1200/JCO.2017.72.4211.
    PubMed     Text format     Abstract available


  50. CHAN FC, Mottok A, Gerrie AS, Power M, et al
    Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
    J Clin Oncol. 2017 Sep 12:JCO2017727925. doi: 10.1200/JCO.2017.72.7925.
    PubMed     Text format     Abstract available


  51. LEONARD JP, Kolibaba KS, Reeves JA, Tulpule A, et al
    Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Sep 1:JCO2017732784. doi: 10.1200/JCO.2017.73.2784.
    PubMed     Text format     Abstract available


    August 2017
  52. MARTINEZ C, Gayoso J, Canals C, Finel H, et al
    Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and
    J Clin Oncol. 2017 Aug 28:JCO2017726869. doi: 10.1200/JCO.2017.72.6869.
    PubMed     Text format     Abstract available


  53. VITOLO U, Trneny M, Belada D, Burke JM, et al
    Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Aug 10:JCO2017733402. doi: 10.1200/JCO.2017.73.3402.
    PubMed     Text format     Abstract available


  54. MOSSE YP, Voss SD, Lim MS, Rolland D, et al
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    J Clin Oncol. 2017 Aug 8:JCO2017734830. doi: 10.1200/JCO.2017.73.4830.
    PubMed     Text format     Abstract available


    July 2017
  55. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Text format     Abstract available


  56. VARGO JA, Ling DC, Beriwal S
    Treatment of Early-Stage Hodgkin Lymphoma: Are We Just Shifting Morbidities?
    J Clin Oncol. 2017 Jul 6:JCO2017733568. doi: 10.1200/JCO.2017.73.3568.
    PubMed     Text format    


  57. HINDIE E, Mesguich C, Zanotti-Fregonara P
    On the Role of Interim Fluorine-18-Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017738369. doi: 10.1200/JCO.2017.73.8369.
    PubMed     Text format    


  58. ADAMS HJA, Kwee TC
    Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017733816. doi: 10.1200/JCO.2017.73.3816.
    PubMed     Text format    


    June 2017
  59. LEONARD JP, Martin P, Roboz GJ
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    J Clin Oncol. 2017 Jun 27:JCO2017726745. doi: 10.1200/JCO.2017.72.6745.
    PubMed     Text format     Abstract available


  60. GROMMES C, DeAngelis LM
    Primary CNS Lymphoma.
    J Clin Oncol. 2017 Jun 22:JCO2017727602. doi: 10.1200/JCO.2017.72.7602.
    PubMed     Text format     Abstract available


    May 2017
  61. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Text format     Abstract available


  62. WITZIG TE
    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed     Text format    


  63. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed     Text format    


  64. LANDSBURG DJ, Falkiewicz MK, Maly J, Blum KA, et al
    Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol. 2017 May 5:JCO2017722157. doi: 10.1200/JCO.2017.72.2157.
    PubMed     Text format     Abstract available


  65. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Text format     Abstract available


  66. LAURENT C, Baron M, Amara N, Haioun C, et al
    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol. 2017 May 1:JCO2016712083. doi: 10.1200/JCO.2016.71.2083.
    PubMed     Text format     Abstract available


    April 2017
  67. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Text format     Abstract available


  68. CHEN R, Zinzani PL, Fanale MA, Armand P, et al
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
    J Clin Oncol. 2017 Apr 25:JCO2016721316. doi: 10.1200/JCO.2016.72.1316.
    PubMed     Text format     Abstract available


  69. THIEBLEMONT C, Tilly H, Gomes da Silva M, Casasnovas RO, et al
    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984.
    PubMed     Text format     Abstract available


  70. SASSE S, Brockelmann PJ, Goergen H, Plutschow A, et al
    Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    J Clin Oncol. 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
    PubMed     Text format     Abstract available


  71. MEYER RM
    Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty.
    J Clin Oncol. 2017 Apr 3:JCO2017722611. doi: 10.1200/JCO.2017.72.2611.
    PubMed     Text format    


    March 2017
  72. ZUCCA E, Conconi A, Martinelli G, Bouabdallah R, et al
    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    J Clin Oncol. 2017 Mar 29:JCO2016706994. doi: 10.1200/JCO.2016.70.6994.
    PubMed     Text format     Abstract available


  73. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Text format     Abstract available


    January 2017
  74. HERRERA AF, Mei M, Low L, Kim HT, et al
    Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    J Clin Oncol. 2017;35:24-31.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: